{
    "nct_id": "NCT06305767",
    "official_title": "A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)",
    "inclusion_criteria": "The main inclusion criteria include but are not limited to the following:\n\n* Must provide blood samples per protocol, to enable V940 production, and circulating tumor deoxyribonucleic acid testing\n* Has an Eastern Cooperative Oncology Group performance status of 0 to 2 assessed within 7 days before randomization\n* Must provide a formalin-fixed paraffin-embedded tumor tissue sample for next generation sequencing\n\nAdjuvant Cohort:\n\n* Has MIUC\n* Has dominant histology of urothelial carcinoma (UC)\n* Has high-risk pathologic disease after radical resection\n* For participants who have not received cisplatin-based neoadjuvant chemotherapy, are ineligible to receive cisplatin according to protocol pre-defined criteria\n\nPerioperative Cohort:\n\n* Has MIBC\n* Has a histological diagnosis of UC\n* Is deemed eligible for RC and PLND and agrees to undergo curative intent standard RC and PLND and neoadjuvant and adjuvant treatment per protocol\n* Is ineligible to receive cisplatin according to protocol pre-defined criteria\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "The main exclusion criteria include but are not limited to the following:\n\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has known additional malignancy that is progressing or has required active treatment â‰¤3 years prior to study randomization\n* Has current pneumonitis/interstitial lung disease\n* Has active infection requiring systemic therapy\n* Has active hepatitis B and hepatitis C virus infection\n\nAdjuvant Cohort:\n\n* Has received prior systemic anticancer therapy\n* Has received prior neoadjuvant therapy, with the exception of neoadjuvant cisplatin-based chemotherapy for MIUC\n* Has severe hypersensitivity to either V940 or pembrolizumab (MK-3475) and/or any of their excipients\n\nPerioperative Cohort:\n\n* Has received any prior systemic treatment, cancer vaccine treatment, chemoradiation, and/or radiation therapy treatment for MIBC\n* Has severe hypersensitivity to either V940, pembrolizumab, or EV and/or any of their excipients\n* Has ongoing sensory or motor neuropathy\n* Has active keratitis or corneal ulcerations",
    "miscellaneous_criteria": ""
}